Relmada Therapeutics, Inc.

NASDAQ:RLMD

Biotechnology

Healthcare
$2.86 -0.97%

-$0.06 today

Market cap
$304.61M
Beta
0.39
P/E (TTM)
-9.6
EPS (TTM)
-$0.68
52W Low $0.52High $8.00

Volume 1.86M

Average 1.24M

RLMD EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Relmada Therapeutics, Inc.NASDAQ: RLMD

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$19.05M, compared with -$17.56M a year earlier. Trailing-twelve-month EBITDA was -$58.88M.

Context

  • EBITDA increased in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 4 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the +28.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$19.05M+4.1% QoQ
Last fiscal yearDec 2025
-$57.39M+28.3% YoY
LTMMar 2026
-$58.88M-297.6% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-8.5%+100.0%+108.5 pp
1 year+28.3%+100.0%+71.7 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(57.39M) USD
Year-over-year change
+28.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How RLMD compares with its peers on the latest reported figures

  • RLMD's LTM Mar 2026 EBITDA of -$58.88M is the 3rd highest of the 9 companies compared; the peer median is -$80.14M.
  • Its year-over-year change of -297.6% is the lowest of 9, against a peer median of +6.0%.
RLMD Competitors Peer median
EBITDA for RLMD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FBIOFortress Biotech, Inc.LTM Mar 2026$148.02M +264.5%—223.7%
VXRTVaxart, Inc.LTM Mar 2026$47.3M +203.4%—18.5%
RLMDRelmada Therapeutics, Inc.LTM Mar 2026-$58.88M -297.6%——
CBUSCibus, Inc.LTM Mar 2026-$62.31M +76.4%—1453.8%
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026-$78.19M +0.2%——
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026-$82.08M +0.7%——
ACETAdicet Bio, Inc.LTM Mar 2026-$102.73M +7.3%——
IMUXImmunic, Inc.LTM Mar 2026-$104.13M -8.2%——
TCRXTScan Therapeutics, Inc.LTM Mar 2026-$118.65M +4.8%—1298.7%
Peer median (excluding RLMD) -$80.14M+6.0%—761.2%

Competitors are the stored peer set for RLMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development90.62M113.32M54.81M46.18M744.56K
Selling, General & Admin35.08M47.93M48.9M37.72M311.9K
Operating Expenses125.7M161.25M103.7M83.89M59.1M
Depreciation & Amortization1.26K2K103.7M00
EBITDA(125.75M)(157.04M)4.91M(79.98M)(57.39M)
EBITDA Margin—————
Operating Income(125.7M)(161.25M)(103.7M)(83.89M)(59.1M)
Operating Margin—————
Interest Income1.2M2.66M5.15M3.53M1.4M
Interest Expense00000
Other Income / Expenses(48.32K)4.21M4.91M3.91M1.72M
Income Before Tax(125.75M)(157.04M)(98.79M)(79.98M)(57.39M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(125.75M)(157.04M)(98.79M)(79.98M)(57.39M)
Net Margin—————
EPS (Basic)(7.16)(5.30)(3.28)(2.65)(1.45)
EPS (Diluted)(7.16)(5.30)(3.28)(2.65)(1.45)
Weighted Avg Shares17.55M29.63M30.1M30.16M39.48M
Weighted Avg Shares (Diluted)17.55M29.63M30.1M30.16M39.48M

Relmada Therapeutics, Inc.

NASDAQ:RLMD

Intrinsic Alpha fair value

Locked

Current Price

$2.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.